| Thursday 19 September | | |
 | Epithelial barrier dysfunction in type 2 inflammatory diseases | 13.00-14.30 |
 | PPARs as conductors of the skin orchestra in health in disease | 13.00-14.30 |
 | Chronic inflammatory diseases: from immunology to personalized medicine | 13.00-14.00 |
| Friday 20 September | | |
 | Immunoglobulin therapy in severe autoimmune skin diseases | 08.30-09.30 |
  | A deep dive into chlormethine gel: from bench to patients | 08.30-09.30 |
 | A new treatment option for patients with moderate-to-severe Atopic Dermatitis: Targeting the IL-31/IL-31R signaling pathway | 08.30-09.30 |
 | Targeting extracellular inflammatory mediators or intracellular pathways for dermatological diseases: Which is better? | 13.00-14.30 |
 | Senescence & Skin Aging | 13.00-14.30 |
 | Pathways to Silencing Psoriasis: Remission or Cure? | 13.00-14.30 |
| | |
